Ligand Pharmaceuticals Stock Rockets 11% With 9-Day Winning Streak
Ligand Pharmaceuticals (LGND) – a developer and acquirer of pharmaceutical drug technologies worldwide – hit a 9-day winning streak, with cumulative gains over this period amounting to 11%. The company’s market cap has surged by about $512 Mil over the last 9 days and currently stands at $5.1 Bil.
Is this an opportunity or a trap? There is not much to fear in LGND stock given its overall Very Strong operating performance and financial condition. Hence, despite its Very High valuation, the stock appears Attractive but Volatile (For details, see Buy or Sell LGND).
But here is the interesting part. You are reading about this 11% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio is based on an architecture that includes such signals.
Returns vs S&P 500
The following table summarizes the return for LGND stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | LGND | S&P 500 |
|---|---|---|
| 1D | 0.4% | 0.5% |
| 9D (Current Streak) | 11.2% | -2.2% |
| 1M (21D) | 15.5% | -0.2% |
| 3M (63D) | 25.9% | 12.1% |
| YTD 2026 | 35.2% | 8.6% |
| 2025 | 76.5% | 16.4% |
| 2024 | 50.0% | 23.3% |
| 2023 | 6.9% | 24.2% |
However, big gains can follow sharp reversals – but how has LGND behaved after prior drops? See LGND Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 59 S&P constituents with 3 days or more of consecutive gains and 22 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 11 | 13 |
| 4D | 35 | 3 |
| 5D | 1 | 0 |
| 6D | 5 | 5 |
| 7D or more | 7 | 1 |
| Total >=3 D | 59 | 22 |
Key Financials for Ligand Pharmaceuticals (LGND)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $167.1 Mil | $268.1 Mil |
| Operating Income | $23.0 Mil | $47.2 Mil |
| Net Income | $-4.0 Mil | $124.5 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ4 | 2026 FQ1 |
|---|---|---|
| Revenues | $59.7 Mil | $51.7 Mil |
| Operating Income | $20.0 Mil | $17.4 Mil |
| Net Income | $44.8 Mil | $-13.3 Mil |
While LGND stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.